CADI-05
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CADI-05, covering 2009-06-11 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas [Phase 1]